Shuta Tomida
Okayama, 7008558, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment.
Journal: Current oncology (Toronto, Ont.)
Published: April 08, 2026
Genomic heterogeneity and clinical implications in gastrointestinal neuroendocrine carcinoma: MYC and KRAS as predictive biomarkers.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.
Journal: Haematologica
Published: November 18, 2025
ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 16, 2025
Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations.
Journal: Cancer science
Published: October 05, 2025
Corrigendum to "Genomic landscape and clinical impact of homologous recombination repair gene mutation in small bowel adenocarcinoma" [Eur J Cancer 220 (2025) 115401].
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 12, 2025
Longitudinal spatial transcriptomics reveals the molecular dynamics of pulmonary artery remodeling in pulmonary arterial hypertension.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: September 09, 2025
Clinical Characteristics and Spatial Transcriptome Analysis of Non-Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study.
Journal: Cancer research communications
Published: September 09, 2025
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.
Journal: Cancer research communications
Published: August 24, 2025
Remarkable response of gastric adenocarcinoma with FGFR2-TRIM44 fusion to pemigatinib: a case report.
Journal: Japanese journal of clinical oncology
Published: August 10, 2025
Last Updated: 09/26/2026